Search

everythinglearnresearchcommunity

for

Search:↓

Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.

New treatments for male hypogonadism are effective and should be personalized.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Skin problems are very common in people with end-stage kidney disease.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

Male pattern baldness is mostly inherited, involves many genes, and is linked to other traits like early puberty and strong bones.

Post-finasteride patients show changed neuroactive steroid levels, possibly causing erectile dysfunction and depression.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Some drugs may reduce prostatitis symptoms short-term with few side effects.

Impaired androgen production in 46,XY DSDs causes ambiguous genitalia and requires long-term care.

Finasteride and spironolactone both reduce hirsutism, but finasteride lowers androgen levels more.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

LGBT individuals have unique skin health needs, including higher STD risks and side effects from gender-affirming treatments, requiring dermatologists to offer knowledgeable and culturally competent care.

Hormone imbalances can cause specific skin changes, which may help in early detection of endocrine disorders.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

Gene therapy has potential as a future treatment for Hutchinson-Gilford progeria syndrome.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

Psychotropic medications can cause skin reactions, including severe conditions like SJS and TEN, and it's important for psychiatrists to recognize and manage these side effects.

Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

Finasteride can cause sexual problems and depression in young men.

The HGCA tool helps identify genes that work together by analyzing their co-expression patterns.

Consider benefits and risks of new alopecia treatments for safety.

Lack or blocking of SRD5a, a key component in hormone creation, can lead to conditions like pseudohermaphrodism and affect hair growth, bone mass, muscle strength, and reproductive health. More research is needed on its regulation from fertilization to adulthood.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.